This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Alopecia  • Hair Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Jeffrey C. Donovan, MD, PhD; Danny M. Ghazarian, MB, ChB, PhD, FRCPC; James C. Shaw, MD, FRCPC

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Follicular eruptions are well-recognized adverse effects of epidermal growth factor receptor (EGFR) inhibitor therapy.¹ Although alopecia is uncommon, mice with targeted disruption of the EGFR develop alopecia.^2-3 We report the development of scarring alopecia associated with use of the EGFR inhibitor gefitinib (Iressa; AstraZeneca, Mississisauga, Ontario, Canada).

Report of a Case

A 70-year-old woman with stage IV non–small cell lung cancer was evaluated regarding a 2-year history of scalp erythema and crusting that progressed to scarring alopecia (Figure 1). The eruption began 8 months after the start of gefitinib therapy, 250 mg/d. However, textural changes and slower hair growth were noted after only 2 months of gefitinib treatment.

Figure appears in full text version. Figure 1. A 70-year-old woman with marked frontal and vertex alopecia that appeared after the use of the epidermal growth factor receptor inhibitor gefitinib. Note the sharp . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?